DE602005010047D1 - Nervenwachstumsfaktor sezernierende menschliche therapeutische zellen - Google Patents

Nervenwachstumsfaktor sezernierende menschliche therapeutische zellen

Info

Publication number
DE602005010047D1
DE602005010047D1 DE602005010047T DE602005010047T DE602005010047D1 DE 602005010047 D1 DE602005010047 D1 DE 602005010047D1 DE 602005010047 T DE602005010047 T DE 602005010047T DE 602005010047 T DE602005010047 T DE 602005010047T DE 602005010047 D1 DE602005010047 D1 DE 602005010047D1
Authority
DE
Germany
Prior art keywords
sezernating
growth factor
nerve growth
therapeutic cells
human therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005010047T
Other languages
English (en)
Inventor
Jens Tornoe
Philip Kusk
Lars Wahlberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NsGene AS
Original Assignee
NsGene AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NsGene AS filed Critical NsGene AS
Publication of DE602005010047D1 publication Critical patent/DE602005010047D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/126—Immunoprotecting barriers, e.g. jackets, diffusion chambers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A61L2300/414—Growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/64—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE602005010047T 2004-01-19 2005-01-18 Nervenwachstumsfaktor sezernierende menschliche therapeutische zellen Active DE602005010047D1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200400064 2004-01-19
US53703304P 2004-01-20 2004-01-20
DKPA200400673 2004-04-30
US57508704P 2004-05-28 2004-05-28
PCT/EP2005/050180 WO2005068498A2 (en) 2004-01-19 2005-01-18 Human therapeutic cells secreting nerve growth factor

Publications (1)

Publication Number Publication Date
DE602005010047D1 true DE602005010047D1 (de) 2008-11-13

Family

ID=34799654

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005010047T Active DE602005010047D1 (de) 2004-01-19 2005-01-18 Nervenwachstumsfaktor sezernierende menschliche therapeutische zellen

Country Status (7)

Country Link
US (1) US20080286323A1 (de)
EP (1) EP1709161B1 (de)
AT (1) ATE409741T1 (de)
DE (1) DE602005010047D1 (de)
DK (1) DK1709161T3 (de)
ES (1) ES2315842T3 (de)
WO (1) WO2005068498A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060014288A1 (en) * 2004-06-23 2006-01-19 Tissuegene, Inc. Nerve regeneration
JP2009513584A (ja) * 2005-10-28 2009-04-02 エヌエスゲーネ・アクティーゼルスカブ Ｇｄｎｆの送達のための移植可能な生体適合性免疫隔離ビヒクル
CN102361971A (zh) * 2009-01-23 2012-02-22 Ns基因公司 改善的细胞系以及在胶囊化细胞生物递送中的用途
WO2011079222A2 (en) 2009-12-23 2011-06-30 Boston Scientific Scimed, Inc. Less traumatic method of delivery of mesh-based devices into human body
CN103732234A (zh) * 2011-01-18 2014-04-16 斯丹姆涅恩有限公司 使伤口愈合的装置和方法
ES2939147T3 (es) 2011-03-18 2023-04-19 Microvascular Tissues Inc Tejido microvascular alogénico para tratamientos de tejidos blandos
JP6039146B2 (ja) * 2011-12-19 2016-12-07 ワッカー ケミー アクチエンゲゼルシャフトＷａｃｋｅｒ Ｃｈｅｍｉｅ ＡＧ 新規なｐｒｏＮＧＦ変異体およびβ−ＮＧＦ製造におけるその使用
CA2856451A1 (en) * 2012-01-05 2013-07-11 Beech Tree Labs, Inc. Method of treating pain by administration of nerve growth factor
US10596202B2 (en) 2012-09-19 2020-03-24 Microvascular Tissues, Inc. Compositions and methods for treating and preventing tissue injury and disease
US11819522B2 (en) 2012-09-19 2023-11-21 Microvascular Tissues, Inc. Compositions and methods for treating and preventing tissue injury and disease
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
US20170266354A1 (en) 2014-09-04 2017-09-21 Kemijski Institut Cell-Based Device For Local Treatment With Therapeutic Protein
US11883464B2 (en) * 2016-03-18 2024-01-30 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Nerve growth factor fusion protein, preparation method and use thereof
GB201610101D0 (en) * 2016-06-09 2016-07-27 Attenborough Dental Laboratories Ltd Multicellular lay-up process
US20180147236A1 (en) * 2016-11-25 2018-05-31 National Taiwan University Method of suppressing inflammation and promoting repair of injured neural tissues with carboxyl-functionalized polyurethane nanoparticles
JP2021509675A (ja) * 2018-01-08 2021-04-01 マイクロバスキュラー ティシューズ， インコーポレイテッド 神経損傷を治療するための組成物および方法
CA3156941A1 (en) * 2019-11-01 2021-05-06 Neurotech Usa, Inc. System, apparatuses, devices, and methods for an analyte diffusive implantable device
CN113845583B (zh) * 2020-06-28 2023-08-11 江苏中新医药有限公司 一种修饰的重组人神经生长因子及其制备方法
CN114933657B (zh) * 2021-08-25 2024-02-02 上海交通大学医学院 神经生长因子突变体重组蛋白及其应用
CN116216874B (zh) * 2023-03-23 2024-04-30 重庆大学 一种控制蓝藻水华的水体修复剂、制备方法和应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169762A (en) * 1983-03-03 1992-12-08 Genentech, Inc. Human nerve growth factor by recombinant technology
US4861719A (en) * 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US5283187A (en) * 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US5158881A (en) * 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US5106627A (en) * 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
US4892538A (en) * 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5156844A (en) * 1987-11-17 1992-10-20 Brown University Research Foundation Neurological therapy system
DE3829752A1 (de) * 1988-09-01 1990-03-22 Akzo Gmbh Integrale asymmetrische polyaethersulfonmembran, verfahren zur herstellung und verwendung zur ultrafiltration und mikrofiltration
DE3829766A1 (de) * 1988-09-01 1990-03-22 Akzo Gmbh Verfahren zur herstellung von membranen
DE69032809T2 (de) * 1989-11-06 1999-07-08 Cell Genesys, Inc., Foster City, Calif. Herstellung von Proteinen mittels homologer Rekombination
US5272071A (en) * 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
US5618531A (en) * 1990-10-19 1997-04-08 New York University Method for increasing the viability of cells which are administered to the brain or spinal cord
US5488099A (en) * 1992-03-06 1996-01-30 Persson, Deceased; Hakan B. Multifunctional chimeric neurotrophic factors
EP0612831B1 (de) * 1992-12-07 1998-03-25 Idemitsu Kosan Company Limited Flammfestes Hydrauliköl
US5512600A (en) * 1993-01-15 1996-04-30 Massachusetts Institute Of Technology Preparation of bonded fiber structures for cell implantation
NZ269041A (en) * 1993-06-23 1998-02-26 Univ Brown Res Found Implantable encapsulation device having a cell-tight dry seal at an opening thereof
DE69430824T2 (de) * 1993-08-12 2003-01-23 Neurotech S.A., Evry Biokompatible immunoisolatorische Kapseln, die genetisch veränderte Zellen enthalten
US5550050A (en) * 1994-04-15 1996-08-27 Cytotherapeutics, Inc. Method for implanting encapsulated cells in a host
US5554146A (en) * 1994-05-06 1996-09-10 Minnesota Mining And Manufacturing Company Mechanical fastener for disposable article
US6299895B1 (en) * 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
US6054142A (en) * 1996-08-01 2000-04-25 Cyto Therapeutics, Inc. Biocompatible devices with foam scaffolds
US6303136B1 (en) * 1998-04-13 2001-10-16 Neurotech S.A. Cells or tissue attached to a non-degradable filamentous matrix encapsulated by a semi-permeable membrane
US6197294B1 (en) * 1998-10-26 2001-03-06 Neurotech S.A. Cell surface molecule-induced macrophage activation
JP3508015B2 (ja) * 1999-12-03 2004-03-22 住友電装株式会社 コネクタ

Also Published As

Publication number Publication date
EP1709161B1 (de) 2008-10-01
EP1709161A2 (de) 2006-10-11
ATE409741T1 (de) 2008-10-15
ES2315842T3 (es) 2009-04-01
US20080286323A1 (en) 2008-11-20
WO2005068498A2 (en) 2005-07-28
WO2005068498A3 (en) 2005-09-22
DK1709161T3 (da) 2009-01-26

Similar Documents

Publication Publication Date Title
DE602005010047D1 (de) Nervenwachstumsfaktor sezernierende menschliche therapeutische zellen
Huang et al. The use of balneotherapy in dermatology
CY1119951T1 (el) Συνθεσεις για αυξηση δραστηριοτητας τελομερασης και αγωγη λοιμωξης hiv
EP2298862A3 (de) Mesenchymale Stammzellen und deren Verwendungen
WO2005116088A3 (en) Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells
ATE531383T1 (de) Therapeutische verwendung eines wachstumsfaktors, metrnl
MX2010001111A (es) Mutantes mcp-1 que antagonizan glicosaminoglicano y metodos para utilizar los mismos.
NZ597779A (en) Treatment of inflammatory diseases using placental stem cells
EA201001695A1 (ru) Применение эпотилона d для лечения заболеваний, связанных с тау-белком
DE602006017071D1 (de) Zusammensetzungen und verfahren zur behandlung von herzkrankheiten
EA200700427A1 (ru) Предупреждение и лечение синуклеинопатических и амилоидогенных заболеваний
ATE385806T1 (de) Fusionsproteine
ATE490984T1 (de) Methode zur produktion und evaluierung der zytotoxizität von kir2dl nk-rezeptor antikörpern
MX2007004551A (es) Compuestos tiadiazol y metodos de uso.
IL177015B (en) Isolated human rpe cells and their use for the treatment of retinal degenerative diseases
MX2007004882A (es) Derivados de xantina con actividad de receptor de hm74a.
CY1118073T1 (el) Συνθεσεις και μεθοδοι για την αυξηση της δρασης της τελομερασης
ATE453642T1 (de) Substituierte phenylaminopyrimidine
DE602004023183D1 (de) Gegen antikörper gerichtete photodynamische therapie
ATE516366T1 (de) Regulierte aptamer-therapeutika
EP1776126A4 (de) Verfahren zur verwendung von regenerativen zellen bei der behandlung von schlaganfall und verwandten erkrankungen und störungen
WO2005094790A8 (es) Formulaciones liposomales
EA200870108A1 (ru) Мутанты фсг
TW200716749A (en) Interferon-beta gene therapy using an improved, regulated expression system
MX2024003893A (es) Piridinas y su uso en el tratamiento de enfermedades relacionadas con gba.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition